These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22653774)

  • 1. Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones.
    Migliori GB; Langendam MW; D'Ambrosio L; Centis R; Blasi F; Huitric E; Manissero D; van der Werf MJ
    Eur Respir J; 2012 Oct; 40(4):814-22. PubMed ID: 22653774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions.
    Shen GH; Tsao TC; Kao SJ; Lee JJ; Chen YH; Hsieh WC; Hsu GJ; Hsu YT; Huang CT; Lau YJ; Tsao SM; Hsueh PR
    Int J Antimicrob Agents; 2012 Mar; 39(3):201-5. PubMed ID: 22285045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Policy-driven revolution of prescription record in outpatient use of fluoroquinolones.
    Kuo SC; Shih SM; Lauderdale TY; Chang IS; Chen YC; Hsiung CA; Chang SC
    J Microbiol Immunol Infect; 2020 Feb; 53(1):133-140. PubMed ID: 29886011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current prospects for the fluoroquinolones as first-line tuberculosis therapy.
    Takiff H; Guerrero E
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5421-9. PubMed ID: 21876059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates.
    Ho J; Jelfs P; Sintchenko V
    Int J Infect Dis; 2014 Sep; 26():149-53. PubMed ID: 25086437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis.
    Zhang D; Gomez JE; Chien JY; Haseley N; Desjardins CA; Earl AM; Hsueh PR; Hung DT
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6600-6608. PubMed ID: 27572408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
    Lee H; Jeong BH; Park HY; Jeon K; Huh HJ; Lee NY; Koh WJ
    Antimicrob Agents Chemother; 2016 Jan; 60(1):471-7. PubMed ID: 26525801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guiding Principles for the use of Fluroquinolones in Out-patient Community Settings of India: Panel Consensus.
    Vora A; Krishnaprasad K
    J Assoc Physicians India; 2017 Aug; 65(8):51-52. PubMed ID: 28799307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.
    Mamatha HG; Shanthi V
    J Glob Antimicrob Resist; 2018 Mar; 12():5-10. PubMed ID: 28887289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Molecular Genetics of Fluoroquinolone Resistance in Mycobacterium tuberculosis.
    Mayer C; Takiff H
    Microbiol Spectr; 2014 Aug; 2(4):MGM2-0009-2013. PubMed ID: 26104201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.
    Grossman RF; Hsueh PR; Gillespie SH; Blasi F
    Int J Infect Dis; 2014 Jan; 18():14-21. PubMed ID: 24211230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017.
    Edwards BD; Edwards J; Cooper R; Kunimoto D; Somayaji R; Fisher D
    PLoS One; 2020; 15(3):e0229691. PubMed ID: 32155169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does radiographic evidence of prior pulmonary tubercular infection influence the choice of empiric antibiotics for community-acquired pneumonia in a tuberculosis-endemic area?
    Jeng YY; Lin YT; Huang LJ; Chen TL; Wang FD; Fung CP; Liu CY
    J Microbiol Immunol Infect; 2010 Oct; 43(5):386-94. PubMed ID: 21075705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empirical use of fluoroquinolones improves the survival of critically ill patients with tuberculosis mimicking severe pneumonia.
    Tseng YT; Chuang YC; Shu CC; Hung CC; Hsu CF; Wang JY
    Crit Care; 2012 Oct; 16(5):R207. PubMed ID: 23098258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High degree of fluoroquinolone resistance among extrapulmonary tuberculosis patients at a tertiary care center in North India.
    Chaubey J; Shrivastava D; Pawar S; Singh BK; Sharma R; Sinha S
    Int J Mycobacteriol; 2020; 9(3):309-312. PubMed ID: 32862166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems.
    Jabeen K; Shakoor S; Hasan R
    Int J Infect Dis; 2015 Mar; 32():118-23. PubMed ID: 25809767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.
    Pranger AD; Alffenaar JW; Aarnoutse RE
    Curr Pharm Des; 2011; 17(27):2900-30. PubMed ID: 21834759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoroquinolone use in a rural practice.
    Kelly L; Schreiber YS; Hopko J; Kirkwood T; Kattini R; Poirier D; Madden S
    Can J Rural Med; 2021; 26(1):14-18. PubMed ID: 33380601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis.
    Salkind AR; Cuddy PG; Foxworth JW
    Ann Pharmacother; 2002 Dec; 36(12):1938-43. PubMed ID: 12452758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of FDA Boxed Warning on Prescribing Patterns of Fluoroquinolones for Uncomplicated Urinary Tract Infections.
    Cowart K; Worley M; Rouby NE; Sando K
    Ann Pharmacother; 2019 Dec; 53(12):1192-1199. PubMed ID: 31319681
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.